Therefore, it would be interesting to study HOOK1 inhibition as a potential treatment for ovarian cancer, either as monotherapy or in combination with chemotherapeutic agents or other drugs inducing proteotoxic stress, such as inhibitors of the proteasome or promoters of the UPR response. This evidence concerns the gene HOOK1 and ovarian cancer.